Screener
Rhythm Pharmaceuticals, Inc. RYTM Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Investing activities | ||
| Purchases of short-term investments | (42,199) | (33,521) |
| Maturities of short-term investments | 99,251 | 58,333 |
| Net cash provided by investing activities | 57,052 | 24,812 |
| Financing activities | ||
| Repayment of deferred royalty obligation | (4,288) | (4,615) |
| Proceeds from the exercise of stock options | 6,095 | 2,226 |
| Tax withholding on vesting of restricted stock | (8,458) | — |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s investing cash flow?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported investing cash flow of $57.05M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s investing cash flow changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s investing cash flow increased by 129.9% year-over-year, from $24.81M to $57.05M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude